Eli Lilly and Co (NYSE:LLY) insider Donald A. Zakrowski sold 876 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $77.55, for a total value of $67,933.80. Following the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at $320,281.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Eli Lilly and Co (LLY) traded up $1.56 during trading on Friday, reaching $78.75. The company’s stock had a trading volume of 5,170,251 shares, compared to its average volume of 6,214,638. Eli Lilly and Co has a 12 month low of $73.69 and a 12 month high of $89.09. The company has a current ratio of 1.32, a quick ratio of 1.03 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $84,569.20, a P/E ratio of -393.73, a P/E/G ratio of 1.44 and a beta of 0.23.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. During the same quarter last year, the business posted $0.95 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. equities analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.86%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently -1,124.94%.
Hedge funds have recently made changes to their positions in the company. Beach Investment Management LLC. purchased a new stake in Eli Lilly and during the 2nd quarter worth about $400,000. NBT Bank N A NY lifted its position in Eli Lilly and by 1.2% during the 2nd quarter. NBT Bank N A NY now owns 11,147 shares of the company’s stock worth $917,000 after acquiring an additional 135 shares in the last quarter. Wesbanco Bank Inc. lifted its position in Eli Lilly and by 0.7% during the 2nd quarter. Wesbanco Bank Inc. now owns 30,921 shares of the company’s stock worth $2,545,000 after acquiring an additional 200 shares in the last quarter. ARGI Investment Services LLC increased its holdings in Eli Lilly and by 31.5% during the 2nd quarter. ARGI Investment Services LLC now owns 3,201 shares of the company’s stock worth $263,000 after purchasing an additional 766 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. increased its holdings in Eli Lilly and by 50.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 9,220 shares of the company’s stock worth $759,000 after purchasing an additional 3,097 shares during the last quarter. Institutional investors and hedge funds own 75.71% of the company’s stock.
Several brokerages recently weighed in on LLY. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 5th. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 price target on shares of Eli Lilly and in a report on Friday, February 2nd. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and increased their price target for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Jefferies Group set a $100.00 price target on Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Bank of America decreased their price target on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. Eli Lilly and currently has an average rating of “Hold” and an average price target of $93.22.
COPYRIGHT VIOLATION WARNING: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/24/eli-lilly-and-co-lly-insider-donald-a-zakrowski-sells-876-shares.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.